Autologous Insulin Producing (AIP) Cells for the Treatment of Diabetes

orgenesis
Pall Corporation
Israel flag

Orgenesis

USA Flag

Pall Corporation

Orgenesis (Israel) collaborated with Pall Corporation (Port Washington, NY) to develop a cell therapy treatment for patients who have diabetes.

In this process, the patient’s cells are harvested and transdifferentiated in bioreactors into functional insulin-producing cells and then transplanted back into the patient to function and produce the insulin needed to regulate the patient’s blood sugar. The technology, supported by the BIRD Foundation, dramatically reduces the investment required to set up a production facility for this treatment and potentially makes it accessible in every cell therapy medical center. Johns Hopkins Hospital (Maryland) uses this innovative technology in its newly built Cell Therapy facility to treat diabetic patients.

Approved 2015

Liked it? share it:

BIRD Foundation
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.